|
| 36878890 | Risk for psychiatric and substance use disorders as a function of transitions in Sweden's public educational system: a national study. | Psychol Med | 2024 |
| 36732589 | Correction: Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. | Mol Psychiatry | 2023 |
| 38026054 | Qualitative Analysis of the Content Validity of the Virtual Reality Functional Capacity Assessment Tool (VRFCAT) in Schizophrenia: A Multi-Stakeholder Perspective. | Schizophr Bull Open | 2023 |
| 37467805 | Using latent profile analyses to classify subjects with anhedonia based on reward-related measures obtained in the FAST-MAS study. | J Affect Disord | 2023 |
| 36965362 | Peripheral inflammation is associated with impairments of inhibitory behavioral control and visual sensorimotor function in psychotic disorders. | Schizophr Res | 2023 |
| 36959619 | Antipsychotic drugs and their effects on cognitive function: protocol for a systematic review, pairwise, and network meta-analysis. | Syst Rev | 2023 |
| 36921403 | Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers. | Schizophr Res | 2023 |
| 36690793 | Cognitive impairment in schizophrenia: aetiology, pathophysiology, and treatment. | Mol Psychiatry | 2023 |
| 36831758 | Impact of Cognitive Impairments on Health-Related Quality of Life in Schizophrenia. | Brain Sci | 2023 |
| 34756932 | Impact of polygenic risk for coronary artery disease and cardiovascular medication burden on cognitive impairment in psychotic disorders. | Prog Neuropsychopharmacol Biol Psychiatry | 2022 |
| 35410496 | Digital Intervention for Cognitive Deficits in Major Depression: A Randomized Controlled Trial to Assess Efficacy and Safety in Adults. | Am J Psychiatry | 2022 |
| 36111288 | Dispersion of cognitive performance test scores on the MATRICS Consensus Cognitive Battery: A different perspective. | Schizophr Res Cogn | 2022 |
| 36096075 | Evaluating how treatment adherence influences cognitive remediation outcomes. | Behav Res Ther | 2022 |
| 36090378 | Remote self-administration of digital cognitive tests using the Brief Assessment of Cognition: Feasibility, reliability, and sensitivity to subjective cognitive decline. | Front Psychiatry | 2022 |
| 35026654 | Social skills, negative symptoms and real-world functioning in individuals at ultra-high risk of psychosis. | Asian J Psychiatr | 2022 |
| 33354862 | A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale. | Early Interv Psychiatry | 2021 |
| 33618939 | Where do we cut the bell-shaped curve of CIAS? | Schizophr Res | 2021 |
| 33610228 | Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: a double-blind, randomised, placebo-controlled phase 2 study. | Lancet Psychiatry | 2021 |
| 34392106 | Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders. | Schizophr Res | 2021 |
| 34145405 | Genome-wide association study accounting for anticholinergic burden to examine cognitive dysfunction in psychotic disorders. | Neuropsychopharmacology | 2021 |
| 34334421 | Virtual Reality Functional Capacity Assessment Tool (VRFCAT-SL) in Parkinson's Disease. | J Parkinsons Dis | 2021 |
| 33429151 | Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. | Schizophr Res | 2021 |
| 33307353 | Can IQ moderate the response to cognitive remediation in people with schizophrenia? | J Psychiatr Res | 2021 |
| 33244149 | Placebo response mitigation with a participant-focused psychoeducational procedure: a randomized, single-blind, all placebo study in major depressive and psychotic disorders. | Neuropsychopharmacology | 2021 |
| 33098300 | Cognitive Subtyping in Schizophrenia: A Latent Profile Analysis. | Schizophr Bull | 2021 |
| 31183960 | Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning. | Early Interv Psychiatry | 2020 |
| 31652174 | Theta Burst for Cognitive Remediation in Schizophrenia: A Case Series and Feasibility Study. | J ECT | 2020 |
| 33334505 | A novel digital intervention for actively reducing severity of paediatric ADHD (STARS-ADHD): a randomised controlled trial. | Lancet Digit Health | 2020 |
| 32690346 | Assessing instrumental activities of daily living (iADL) with a game-based assessment for individuals with schizophrenia. | Schizophr Res | 2020 |
| 32616360 | A new measure of authentic auditory emotion recognition: Application to patients with schizophrenia. | Schizophr Res | 2020 |
| 32639514 | Requisite Skills and the Meaningful Measurement of Cognition. | JAMA Psychiatry | 2020 |
| 32336305 | Corticolimbic brain anomalies are associated with cognitive subtypes in psychosis: A longitudinal study. | Eur Psychiatry | 2020 |
| 32322540 | Verbal memory measurement towards digital perspectives in first-episode psychosis: A review. | Schizophr Res Cogn | 2020 |
| 32231295 | A randomized proof-of-mechanism trial applying the 'fast-fail' approach to evaluating κ-opioid antagonism as a treatment for anhedonia. | Nat Med | 2020 |
| 29718385 | Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial. | Schizophr Bull | 2019 |
| 31431890 | Approaches to attenuated psychosis syndrome treatments: A perspective on the regulatory issues. | Schizophr Res Cogn | 2019 |
| 31196736 | Comprehensive review of the research employing the schizophrenia cognition rating scale (SCoRS). | Schizophr Res | 2019 |
| 31059617 | Why are there no approved treatments for cognitive impairment in schizophrenia? | World Psychiatry | 2019 |
| 30930034 | Evaluation of a plasticity-based cognitive training program in schizophrenia: Results from the eCaesar trial. | Schizophr Res | 2019 |
| 30268821 | Basic auditory processing deficits and their association with auditory emotion recognition in schizophrenia. | Schizophr Res | 2019 |
| 30679049 | Virtual reality assessment of functional capacity in people with Schizophrenia: Associations with reduced emotional experience and prediction of functional outcomes. | Psychiatry Res | 2019 |
| 28545944 | Deviation from expected cognitive ability across psychotic disorders. | Schizophr Res | 2018 |
| 30028891 | What is the overlap between subjective and objective cognitive impairments in MDD? | Ann Clin Psychiatry | 2018 |
| 29804925 | Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis. | Schizophr Res | 2018 |
| 30046827 | Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis. | JAMA Psychiatry | 2018 |
| 30094331 | TOMMORROW neuropsychological battery: German language validation and normative study. | Alzheimers Dement (N Y) | 2018 |
| 29873956 | Cognitive Effects of MIN-101 in Patients With Schizophrenia and Negative Symptoms: Results From a Randomized Controlled Trial. | J Clin Psychiatry | 2018 |
| 30591715 | The first implementation of the NIMH FAST-FAIL approach to psychiatric drug development. | Nat Rev Drug Discov | 2018 |
| 30409386 | Take This Cognitive Training Efficacy Bar Fight Outside (to a Regulatory Agency). | Biol Psychiatry Cogn Neurosci Neuroimaging | 2018 |
| 30298179 | Assessment of Instrumental Activities of Daily Living in Older Adults with Subjective Cognitive Decline Using the Virtual Reality Functional Capacity Assessment Tool (VRFCAT). | J Prev Alzheimers Dis | 2018 |